Seeking Alpha

The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical...

The Street's Adam Feuerstein wonders whether AstraZeneca's (AZN) and Nektar's (NKTR) critical naloxegol product for opioid-induced constipation failed one of its Phase III trials rather than passed it, as the companies indicate. Feuerstein's skepticism is based on AZN retrieving data from one patient that was thought to be non-retrievable after the database for the trial had been locked.
Comments (1)
  • mitrado
    , contributor
    Comments (1961) | Send Message
     
    This guy is a Troll. Why does he get so much attention?

     

    Disclaimer: I am not invested in AZN in any way. It's on my watchlist, waiting for a lower entry price... and this little b*tch's stories might just give me that chance.
    13 Nov 2012, 10:53 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector

Next headline on your portfolio:

|